{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-029710","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2026-06-23T12:30:46+00:00","discovered_at":"2026-06-23T12:35:00.555249+00:00","generated_at":"2026-06-23T12:35:31.463197+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Calidi Biotherapeutics appoints Dr. Corsee Sanders to board; board expands to six","bullets":["Dr. Corsee Sanders appointed as Class III director effective June 17, 2026, term to 2029 annual meeting.","Board size increased from 5 to 6; Scott Leftwich removed from Audit Committee but remains on board.","Sanders brings 30+ years pharma experience including Genentech/Roche SVP and Juno/Celgene EVP roles.","Initial equity award for Sanders deferred pending board assessment of available shares under equity plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-029710","json":"https://secwatch.observer/filing/0001493152-26-029710.json","markdown":"https://secwatch.observer/filing/0001493152-26-029710.md","text":"https://secwatch.observer/filing/0001493152-26-029710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226029710/0001493152-26-029710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226029710/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T12:35:31.463197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}